Hadassah

FDA Grants Approval for US Clinical Trials of Hadassah-Developed Technology to Treat Fatty Liver Disease

Wednesday, Dec 17 2014

A new drug technology, developed at the Hadassah Medical Organization to treat fatty liver disease--a condition with no approved effective drug treatment--was given the go-ahead by the United States Food and Drug Administration (FDA) for a Phase 2 multi-center clinical trial in the US.

In its severe form (called nonalcoholic steatohepatitis-NASH), fatty liver disease can lead to cirrhosis and liver cancer. Current estimates reveal that at least five percent of the Western world’s population suffers from the disease. The majority of these patients also have diabetes, high blood lipids, and obesity.

The new technology was developed by Prof. Yaron Ilan, Director, Department of Internal Medicine and former president of the Israel Liver Association, and his team in Hadassah’s Liver Unit. Based on feeding natural antibodies against intestinal bacteria associated with fatty liver disease, the treatment reduces inflammation by directly affecting the activity level of regulatory T cells in the liver and fat tissues. “The new drug is based on a novel discovery that bacteria in our gut are relevant for the induction of inflammation in our body, which is associated with liver disease, diabetes, and obesity” said Prof. Ilan. “The new therapy is safe and has no side effect, and we hope the results of the phase II trial will enable us to move forward with its development as a treatment for diabetes and fatty liver disease”.

Hadasit, Hadassah’s technology transfer arm, and Immuron, an Australian biopharmaceutical company, worked together to develop the product. The collaborative effort combines Hadassah’s oral immune modulation approach with antibodies produced by Immuron.

The multi-center clinical trial will involve 120 patients in several leading medical centers in the US and Australia. The cohort will receive the treatment for six months, while monitored for the state of their liver disease, diabetes, and lipid profile.

Clinical trials were already conducted at Hadassah, which confirmed the safety and efficacy of the treatment.

Read about the 2009 discovery of treatment for fatty liver disease

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Friday, Mar 8 2019

Quick Action at Hadassah’s Milstein Heart Center Saves Exuberant Hasidic Dancer

“You can’t dance at all the weddings” is a common Hebrew and Yiddish expression. For Mr. Cohen (not his real name), a 49-year-old teacher, the wedding of a friend’s son was an occasion to get together with classmates from his post-high school yeshiva days when he was 19. Inclined to dance with joy at weddings, this twinkle-eyed, bearded Hassid increased the tempo in the presence of his long-ago pals.

READ MORE ›
alt_text

Friday, Mar 8 2019

Hadassah Surgeon Uses Revolutionary Surgery and Stem Cells to Restore Mobility

He grew up on the Mediterranean coast in Ashkelon, but Eyal Turgeman dreamed of becoming an African wilderness tour guide. After serving in the Israel Defense Forces’  elite paratroopers unit, he arrived in Namibia, a southwestern African country marked by rocky trails, sunshine, and sandy open spaces.

READ MORE ›
alt_text

Wednesday, Feb 27 2019

A Double Stroke at the Dead Sea

Imagine having a double stroke in two different arteries while on a day trip at the Dead Sea! What could be the chances of survival?

READ MORE ›
alt_text

Wednesday, Feb 27 2019

A Miracle in the Medical Intensive Care Unit at Hadassah —as recalled by Dr. Sigal Sviri, Director

On a cold December morning, a 26-year-old mother of two started developing flu symptoms, with fever, headache, and shortness of breath. As her breathing got worse, she came to the emergency room at Hadassah Hospital Ein Kerem and was admitted to the Medical Intensive Care Unit (MICU).

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More